Dublin-based biotech Aerska recently secured $21 million in a financing round led by Age1, Backed VC, and Speedinvest to advance its RNA interference (RNAi) therapeutics. The company focuses on overcoming the blood-brain barrier to treat neurological diseases, prioritizing genetic forms of Alzheimer's and Parkinson’s. CEO Jack O'Meara emphasized leveraging a modular RNAi platform aimed at high-quality data generation to accelerate program development and ultimately transform neurologic disease treatment. The investment marks a key step toward addressing underserved neurological conditions through innovative delivery mechanisms.